Mary Ann Mascelli, Ph.D., has more than 25 years of academic and pharmaceutical industry experience in the areas of non-clinical / clinical pharmacology and translational research. Dr. Mascelli has extensive experience in the design, execution, analysis, and reporting of late non-clinical and early clinical development studies characterizing the disposition (PK) and pharmacodynamic properties of experimental therapeutics. She had incorporated translational science strategies resulting in establishing of “proof of concept” early clinical studies. She has pre-clinical / clinical development experience across a broad spectrum of molecular platforms, including small molecule and biotherapeutics (monoclonal antibodies enzyme replacement therapies and siRNA therapeutics). Dr Mascelli has authored numerous non-clinical and clinical pharmacology Modules for IND / BLA submissions and has acted as the DMPK Subject Matter Expert for Regulatory Interactions. Her therapeutic area experience includes cardiovascular, hematology, respiratory, inflammation/autoimmunity and rare diseases. Dr Mascelli has authored / co-authored over 60 peer-reviewed and review articles. Prior to working at Nuventra, she worked at BioBridges, Shire, MedImmune, and Johnson & Johnson.